Annual EBIT
$1.89 B
-$1.75 B-48.15%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual earnings before interest & taxes is $1.89 billion, with the most recent change of -$1.75 billion (-48.15%) on March 31, 2024.
- During the last 3 years, TAK annual EBIT has fallen by -$2.80 billion (-59.70%).
- TAK annual EBIT is now -64.70% below its all-time high of $5.35 billion, reached on March 31, 2007.
Performance
TAK EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$380.27 M
-$884.25 M-69.93%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly earnings before interest & taxes is $380.27 million, with the most recent change of -$884.25 million (-69.93%) on December 1, 2024.
- Over the past year, TAK quarterly EBIT has dropped by -$884.25 million (-69.93%).
- TAK quarterly EBIT is now -85.84% below its all-time high of $2.69 billion, reached on June 30, 2021.
Performance
TAK Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$2.23 B
-$485.46 M-17.91%
December 1, 2024
Summary
- As of February 7, 2025, TAK TTM earnings before interest & taxes is $2.23 billion, with the most recent change of -$485.46 million (-17.91%) on December 1, 2024.
- Over the past year, TAK TTM EBIT has dropped by -$485.46 million (-17.91%).
- TAK TTM EBIT is now -63.45% below its all-time high of $6.09 billion, reached on September 30, 2021.
Performance
TAK TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TAK EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -48.1% | -69.9% | -17.9% |
| 3 y3 years | -59.7% | +31.8% | -45.7% |
| 5 y5 years | +19.2% | -54.4% | -52.5% |
TAK EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -59.7% | at low | -76.6% | +156.1% | -59.4% | +88.0% |
| 5 y | 5-year | -59.7% | +132.7% | -85.8% | +145.2% | -63.5% | +124.4% |
| alltime | all time | -64.7% | +283.6% | -85.8% | +113.8% | -63.5% | +281.0% |
Takeda Pharmaceutical Company Limited EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | $380.27 M(-69.9%) | $2.23 B(-17.9%) |
| Sep 2024 | - | $1.26 B(+0.4%) | $2.71 B(+129.0%) |
| Jun 2024 | - | $1.26 B(-285.7%) | $1.18 B(-11.8%) |
| Mar 2024 | $1.89 B(-48.2%) | -$678.16 M(-178.3%) | $1.34 B(-41.9%) |
| Dec 2023 | - | $865.73 M(-429.4%) | $2.31 B(-16.6%) |
| Sep 2023 | - | -$262.78 M(-118.5%) | $2.77 B(-28.8%) |
| Jun 2023 | - | $1.42 B(+391.4%) | $3.89 B(-5.1%) |
| Mar 2023 | $3.64 B(-3.7%) | $288.62 M(-78.2%) | $4.10 B(+29.6%) |
| Dec 2022 | - | $1.33 B(+54.7%) | $3.16 B(+9.7%) |
| Sep 2022 | - | $856.73 M(-47.4%) | $2.88 B(-2.1%) |
| Jun 2022 | - | $1.63 B(-351.7%) | $2.95 B(-26.4%) |
| Mar 2022 | $3.79 B(-19.3%) | -$646.91 M(-161.9%) | $4.00 B(-27.0%) |
| Dec 2021 | - | $1.05 B(+13.8%) | $5.48 B(-9.9%) |
| Sep 2021 | - | $918.73 M(-65.8%) | $6.09 B(+6.3%) |
| Jun 2021 | - | $2.69 B(+222.2%) | $5.73 B(+22.2%) |
| Mar 2021 | $4.69 B(+477.4%) | $833.68 M(-49.5%) | $4.69 B(+55.6%) |
| Dec 2020 | - | $1.65 B(+196.3%) | $3.01 B(+51.2%) |
| Sep 2020 | - | $557.28 M(-66.1%) | $1.99 B(-6.3%) |
| Jun 2020 | - | $1.65 B(-295.5%) | $2.13 B(+114.4%) |
| Mar 2020 | $812.03 M(-48.8%) | -$842.09 M(-233.5%) | $992.02 M(-14.6%) |
| Dec 2019 | - | $630.68 M(-8.9%) | $1.16 B(+0.9%) |
| Sep 2019 | - | $692.29 M(+35.4%) | $1.15 B(+0.9%) |
| Jun 2019 | - | $511.14 M(-175.9%) | $1.14 B(-29.9%) |
| Mar 2019 | $1.59 B(-22.7%) | -$673.13 M(-208.6%) | $1.62 B(+6.3%) |
| Dec 2018 | - | $619.78 M(-9.1%) | $1.53 B(+5.1%) |
| Sep 2018 | - | $682.08 M(-31.5%) | $1.45 B(+27.6%) |
| Jun 2018 | - | $996.22 M(-229.5%) | $1.14 B(-43.5%) |
| Mar 2018 | $2.05 B(+47.0%) | -$769.48 M(-240.9%) | $2.02 B(-5.2%) |
| Dec 2017 | - | $546.13 M(+48.6%) | $2.13 B(-0.0%) |
| Sep 2017 | - | $367.53 M(-80.4%) | $2.13 B(+13.9%) |
| Jun 2017 | - | $1.87 B(-384.4%) | $1.87 B(+30.6%) |
| Mar 2017 | $1.40 B(+9.8%) | -$658.92 M(-220.5%) | $1.43 B(-20.8%) |
| Dec 2016 | - | $546.97 M(+404.8%) | $1.81 B(+2.6%) |
| Sep 2016 | - | $108.36 M(-92.5%) | $1.76 B(-20.8%) |
| Jun 2016 | - | $1.44 B(-605.6%) | $2.22 B(+79.7%) |
| Mar 2016 | $1.27 B | -$283.93 M(-156.7%) | $1.24 B(-200.7%) |
| Dec 2015 | - | $500.74 M(-12.4%) | -$1.23 B(+27.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | $571.59 M(+27.2%) | -$966.10 M(-0.1%) |
| Jun 2015 | - | $449.45 M(-116.3%) | -$967.28 M(+29.8%) |
| Mar 2015 | -$1.03 B(-154.4%) | -$2.75 B(-460.0%) | -$745.42 M(-143.0%) |
| Dec 2014 | - | $764.42 M(+34.0%) | $1.73 B(-4.5%) |
| Sep 2014 | - | $570.41 M(-15.0%) | $1.82 B(-7.8%) |
| Jun 2014 | - | $671.31 M(-346.5%) | $1.97 B(+2.8%) |
| Mar 2014 | $1.89 B(+1.9%) | -$272.36 M(-132.2%) | $1.92 B(-5.6%) |
| Dec 2013 | - | $846.43 M(+17.0%) | $2.03 B(+24.5%) |
| Sep 2013 | - | $723.18 M(+16.9%) | $1.63 B(+1.2%) |
| Jun 2013 | - | $618.49 M(-487.3%) | $1.61 B(-17.3%) |
| Mar 2013 | $1.86 B(-42.4%) | -$159.71 M(-135.7%) | $1.95 B(+12.3%) |
| Dec 2012 | - | $447.83 M(-36.4%) | $1.73 B(-22.5%) |
| Sep 2012 | - | $703.99 M(-26.2%) | $2.24 B(-17.1%) |
| Jun 2012 | - | $954.50 M(-356.2%) | $2.70 B(-15.9%) |
| Mar 2012 | $3.22 B(-25.6%) | -$372.52 M(-139.1%) | $3.21 B(-20.0%) |
| Dec 2011 | - | $952.55 M(-18.3%) | $4.02 B(-8.9%) |
| Sep 2011 | - | $1.17 B(-20.4%) | $4.41 B(-5.4%) |
| Jun 2011 | - | $1.47 B(+239.5%) | $4.66 B(+7.7%) |
| Mar 2011 | $4.33 B(-3.7%) | $431.50 M(-68.0%) | $4.33 B(-1.9%) |
| Dec 2010 | - | $1.35 B(-5.1%) | $4.41 B(+1.6%) |
| Sep 2010 | - | $1.42 B(+25.4%) | $4.34 B(+3.8%) |
| Jun 2010 | - | $1.13 B(+119.3%) | $4.18 B(-6.4%) |
| Mar 2010 | $4.50 B(+11.7%) | $516.02 M(-59.6%) | $4.47 B(-5.2%) |
| Dec 2009 | - | $1.28 B(+1.3%) | $4.72 B(-6.1%) |
| Sep 2009 | - | $1.26 B(-11.0%) | $5.02 B(+5.0%) |
| Jun 2009 | - | $1.42 B(+85.6%) | $4.78 B(+42.1%) |
| Mar 2009 | $4.02 B(-20.5%) | $762.82 M(-51.8%) | $3.37 B(+29.3%) |
| Dec 2008 | - | $1.58 B(+55.4%) | $2.60 B(+155.4%) |
| Sep 2008 | - | $1.02 B | $1.02 B |
| Mar 2008 | $5.06 B(-5.4%) | - | - |
| Mar 2007 | $5.35 B(+16.7%) | - | - |
| Mar 2006 | $4.58 B(+11.4%) | - | - |
| Mar 2005 | $4.11 B(+3.8%) | - | - |
| Mar 2004 | $3.96 B(+11.5%) | - | - |
| Mar 2003 | $3.55 B(+18.5%) | - | - |
| Mar 2002 | $3.00 B(+25.2%) | - | - |
| Mar 2001 | $2.39 B(+30.1%) | - | - |
| Mar 2000 | $1.84 B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
- What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
The current annual EBIT of TAK is $1.89 B
What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual earnings before interest & taxes is $5.35 B
What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
Over the past year, TAK annual earnings before interest & taxes has changed by -$1.75 B (-48.15%)
What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
The current quarterly EBIT of TAK is $380.27 M
What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly earnings before interest & taxes is $2.69 B
What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
Over the past year, TAK quarterly earnings before interest & taxes has changed by -$884.25 M (-69.93%)
What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
The current TTM EBIT of TAK is $2.23 B
What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM earnings before interest & taxes is $6.09 B
What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
Over the past year, TAK TTM earnings before interest & taxes has changed by -$485.46 M (-17.91%)